The Gluon Propagator in the Coulomb Gauge

We give the results for all the one-loop propagators, including finite parts, in the Coulomb gauge. In finite parts we find new non-rational functions in addition to the single logarithms of the Feynman gauge. Of course, the two gauges must agree for any gauge invariant function. We revise the manuscript hep-th/0311118v2 and Eur.Phys.J.C37, 307-313(2004) in accordance with the notation and correct Feynman rules for the Coulomb gauge in Minkowski space found in [16]. The high-energy behaviour of the proper two-point functions is added in Appendix C.Comment: 14 pages, 9 figures, discussion extented, accepted for publication in Eur. Phys. J.

Renormalization in Coulomb gauge QCD

In the Coulomb gauge of QCD, the Hamiltonian contains a non-linear Christ-Lee term, which may alternatively be derived from a careful treatment of ambiguous Feynman integrals at 2-loop order. We investigate how and if UV divergences from higher order graphs can be consistently absorbed by renormalization of the Christ-Lee term. We find that they cannot.Comment: 23 pages, 26 figure

Feynman rules for Coulomb gauge QCD

The Coulomb gauge in nonabelian gauge theories is attractive in principle, but beset with technical difficulties in perturbation theory. In addition to ordinary Feynman integrals, there are, at 2-loop order, Christ-Lee (CL) terms, derived either by correctly ordering the operators in the Hamiltonian, or by resolving ambiguous Feynman integrals. Renormalization theory depends on the subgraph structure of ordinary Feynamn graphs. The CL terms do not have subgraph structure. We show how to carry out enormalization in the presene of CL terms, by re-expressing these as `pseudo-Feynman' inegrals. We also explain how energy divergences cancel.Comment: 8 pages, 10 figue

Expanding Disease Definitions in Guidelines and Expert Panel Ties to Industry:A Cross-sectional Study of Common Conditions in the United States

BACKGROUND: Financial ties between health professionals and industry may unduly influence professional judgments and some researchers have suggested that widening disease definitions may be one driver of over-diagnosis, bringing potentially unnecessary labeling and harm. We aimed to identify guidelines in which disease definitions were changed, to assess whether any proposed changes would increase the numbers of individuals considered to have the disease, whether potential harms of expanding disease definitions were investigated, and the extent of members' industry ties. METHODS AND FINDINGS: We undertook a cross-sectional study of the most recent publication between 2000 and 2013 from national and international guideline panels making decisions about definitions or diagnostic criteria for common conditions in the United States. We assessed whether proposed changes widened or narrowed disease definitions, rationales offered, mention of potential harms of those changes, and the nature and extent of disclosed ties between members and pharmaceutical or device companies. Of 16 publications on 14 common conditions, ten proposed changes widening and one narrowing definitions. For five, impact was unclear. Widening fell into three categories: creating “pre-disease”; lowering diagnostic thresholds; and proposing earlier or different diagnostic methods. Rationales included standardising diagnostic criteria and new evidence about risks for people previously considered to not have the disease. No publication included rigorous assessment of potential harms of proposed changes. Among 14 panels with disclosures, the average proportion of members with industry ties was 75%. Twelve were chaired by people with ties. For members with ties, the median number of companies to which they had ties was seven. Companies with ties to the highest proportions of members were active in the relevant therapeutic area. Limitations arise from reliance on only disclosed ties, and exclusion of conditions too broad to enable analysis of single panel publications. CONCLUSIONS: For the common conditions studied, a majority of panels proposed changes to disease definitions that increased the number of individuals considered to have the disease, none reported rigorous assessment of potential harms of that widening, and most had a majority of members disclosing financial ties to pharmaceutical companies. Please see later in the article for the Editors' Summar

A systematic review of associations between environmental exposures and development of asthma in children aged up to 9 years

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.Peer reviewedPublisher PD

How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review

Objective To assess how well B-type natriuretic peptide (BNP) predicts prognosis in patients with heart failure. Design Systematic review of studies assessing BNP for prognosis m patients with heart failure or asymptomatic patients. Data sources Electronic searches of Medline and Embase from January 1994 to March 2004 and reference lists of included studies. Study selection and data extraction We included all studies that estimated the relation between BNP measurement and the risk of death, cardiac death, sudden death, or cardiovascular event in patients with heart failure or asymptomatic patients, including initial values and changes in values in response to treatment. Multivariable models that included both BNP and left ventricular ejection fraction as predictors were used to compare the prognostic value of each variable. Two reviewers independently selected studies and extracted data. Data synthesis 19 studies used BNP to estimate the relative risk of death or cardiovascular events in heart failure patients and five studies in asymptomatic patients. In heart failure patients, each 100 pg/ml increase was associated with a 35% increase in the relative risk of death. BNP was used in 35 multivariable models of prognosis. In nine of the models, it was the only variable to reach significance-that is, other variables contained no prognostic information beyond that of BNP. Even allowing for the scale of the variables, it seems to be a strong indicator of risk. Conclusion Although systematic reviews of prognostic studies have inherent difficulties, including die possibility of publication bias, the results of the studies in this review show that BNP is a strong prognostic indicator for both asymptomatic patients mid for patients with heart failure at all stages of disease

Renormalization-group Calculation of Color-Coulomb Potential

We report here on the application of the perturbative renormalization-group to the Coulomb gauge in QCD. We use it to determine the high-momentum asymptotic form of the instantaneous color-Coulomb potential $V(\vec{k})$ and of the vacuum polarization $P(\vec{k}, k_4)$. These quantities are renormalization-group invariants, in the sense that they are independent of the renormalization scheme. A scheme-independent definition of the running coupling constant is provided by $\vec{k}^2 V(\vec{k}) = x_0 g^2(\vec{k}/\Lambda_{coul})$, and of $\alpha_s \equiv {{g^2(\vec{k} / \Lambda_{coul})} \over {4\pi}}$, where $x_0 = {{12N} \over {11N - 2N_f}}$, and $\Lambda_{coul}$ is a finite QCD mass scale. We also show how to calculate the coefficients in the expansion of the invariant $\beta$-function $\beta(g) \equiv |\vec{k}| {{\partial g} \over{\partial |\vec{k}|}} = -(b_0 g^3 + b_1 g^5 +b_2 g^7 + ...)$, where all coefficients are scheme-independent.Comment: 24 pages, 1 figure, TeX file. Minor modifications, incorporating referee's suggestion

Effect of two behavioural 'nudging' interventions on management decisions for low back pain: A randomised vignette-based study in general practitioners

Objective €Nudges' are subtle cognitive cues thought to influence behaviour. We investigated whether embedding nudges in a general practitioner (GP) clinical decision support display can reduce low-value management decisions. Methods Australian GPs completed four clinical vignettes of patients with low back pain. Participants chose from three guideline-concordant and three guideline-discordant (low-value) management options for each vignette, on a computer screen. A 2×2 factorial design randomised participants to two possible nudge interventions: €partition display' nudge (low-value options presented horizontally, high-value options listed vertically) or €default option' nudge (high-value options presented as the default, low-value options presented only after clicking for more). The primary outcome was the proportion of scenarios where practitioners chose at least one of the low-value care options. Results 120 GPs (72% male, 28% female) completed the trial (n=480 vignettes). Participants using a conventional menu display without nudges chose at least one low-value care option in 42% of scenarios. Participants exposed to the default option nudge were 44% less likely to choose at least one low-value care option (OR 0.56, 95%CI 0.37 to 0.85; p=0.006) compared with those not exposed. The partition display nudge had no effect on choice of low-value care (OR 1.08, 95%CI 0.72 to 1.64; p=0.7). There was no interaction between the nudges (OR 0.94, 95% CI 0.41 to 2.15; p=0.89). Interpretation A default option nudge reduced the odds of choosing low-value options for low back pain in clinical vignettes. Embedding high value options as defaults in clinical decision support tools could improve quality of care. More research is needed into how nudges impact clinical decision-making in different contexts

The challenge of overdiagnosis begins with its definition

Overdiagnosis means different things to different people. S M Carter and colleagues argue that we should use a broad term such as too much medicine for advocacy and develop precise, case by case definitions of overdiagnosis for research and clinical purposes The implicit social contract underpinning healthcare is that it will reduce illness and preventable death and improve quality of life. But sometimes these promises are not delivered. Sometimes health services take people who don’t need intervention, subject them to tests, label them as sick or at risk, provide unnecessary treatments, tell them to live differently, or insist on monitoring them regularly.1 These interventions don’t improve things for people; they produce complications or illness, reduce quality of life, or even cause premature death. Active health intervention is not always a good thing: it can be “too much medicine,” or produce what is often called overdiagnosis. Although the concept of overdiagnosis has been described in the literature for nearly 50 years in relation to cancer screening,2 3 it was Welch and colleagues’ 2011 book, Overdiagnosed: Making People Sick in the Pursuit of Health, that popularised the term.4 Overdiagnosis is now an acknowledged problem for patients, clinicians, researchers, and policymakers; it is discussed in journals5 6 7 and at specialist conferences8 and addressed through policy and practice initiatives.9 10 11 There is, however, no formal, agreed definition of overdiagnosis. Rather, the word has become a banner under which disparate people with similar general concerns can unite. This vagueness and breadth allows the appearance of unity but does not serve the more exacting demands of research and healthcare. Here we examine the meanings of overdiagnosis more closely and discuss related challenges for healthcare professionals, patients, and researchers. If overdiagnosis is to be understood and mitigated, the broad concept should be subdivided into different problems and its ethical dimensions better acknowledged.NHMR